Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
NCT ID: NCT00329446
Last Updated: 2009-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
800 participants
INTERVENTIONAL
2006-04-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
NCT00329264
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
NCT00389064
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
NCT00322595
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
NCT00326144
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
NCT00278941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine Fumarate
Escitalopram oxylate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to understand and comply with the requirements of the study.
* Able to understand and provide written informed consent
Exclusion Criteria
* Current or past diagnosis of stroke or transient ischemic attack (TIA).
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders Neijber, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Beverly Hills, California, United States
Research Site
Burbank, California, United States
Research Site
La Mesa, California, United States
Research Site
Orange, California, United States
Research Site
Pasadena, California, United States
Research Site
San Diego, California, United States
Research Site
Sherman Oaks, California, United States
Research Site
Upland, California, United States
Research Site
Wildomar, California, United States
Research Site
New Britain, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Boca Raton, Florida, United States
Research Site
Bradenton, Florida, United States
Research Site
DeLand, Florida, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Fort Myers, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Edwardsville, Illinois, United States
Research Site
Merrillville, Indiana, United States
Research Site
Terre Haute, Indiana, United States
Research Site
Newton, Kansas, United States
Research Site
Prairie Village, Kansas, United States
Research Site
Owensboro, Kentucky, United States
Research Site
Lake Charles, Louisiana, United States
Research Site
Baltimore, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Haverhill, Massachusetts, United States
Research Site
Okemos, Michigan, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
St Louis, Missouri, United States
Research Site
Kenilworth, New Jersey, United States
Research Site
Princeton, New Jersey, United States
Research Site
Toms River, New Jersey, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
New York, New York, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Cleveland, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Eugene, Oregon, United States
Research Site
Salem, Oregon, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Memphis, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Richmond, Virginia, United States
Research Site
Kirkland, Washington, United States
Research Site
Spokane, Washington, United States
Research Site
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Montgomery SA, Locklear JC, Svedsater H, Eriksson H. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.
Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011 Dec;26(8):614-28. doi: 10.1002/hup.1256. Epub 2011 Dec 6.
Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012 Jan;27(1):40-54. doi: 10.1097/YIC.0b013e32834d9f49.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GOLD
Identifier Type: -
Identifier Source: secondary_id
D1448C00010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.